SL, by 2017 we will know if the FDA approves or not. If it approves and Pfizer decides to market Vitaros in the US, the company will get a chunk of change...not the full $25M but hopefully a significant amount. By 2017 I agree that the company expects sales milestones from Europe (see below). So after streamlining, and with milestone payments, I can see that 2017 might be profitable. Just a reminder on the level of the sales milestones, they are listed in the third numbers column. That is a lot of change in the company's pocket if and when any of those sales milestones are realized. This table is from page 9 of the recent 10K. Of course, it would be nice to know what level of sales would trigger any of these milestone payments.
sec.gov
Sandoz
|
|
$
|
319
|
|
|
$
|
1,500
|
|
|
$
|
45,613
|
|
|
$
|
47,432
|
|
Recordati
|
|
—
|
|
|
1,093
|
|
|
37,692
|
|
|
38,785
|
|
Takeda
|
|
437
|
|
|
—
|
|
|
36,600
|
|
|
37,037
|
|
Allergan
|
|
—
|
|
|
25,000
|
|
|
—
|
|
|
25,000
|
|
Majorelle
|
|
2,000
|
|
|
—
|
|
|
16,934
|
|
|
18,934
|
|
Ferring
|
|
2,000
|
|
|
—
|
|
|
14,000
|
|
|
16,000
|
|
Mylan
|
|
225
|
|
|
—
|
|
|
13,000
|
|
|
13,225
|
|
Bracco
|
|
—
|
|
|
—
|
|
|
4,916
|
|
|
4,916
|
|
Neopharm
|
|
250
|
|
|
—
|
|
|
4,000
|
|
|
4,250
|
|
Elis
|
|
100
|
|
|
—
|
|
|
1,900
|
|
|
2,000
|
|
|
|
